B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TRPV1

MOLECULAR TARGET

transient receptor potential cation channel subfamily V member 1

UniProt: Q8NER1NCBI Gene: 744220 compounds

TRPV1 (transient receptor potential cation channel subfamily V member 1) is targeted by 20 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TRPV1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1anandamide4.1663
2propofol4.0154
3capsazepine3.5634
4oleoylethanolamide3.5333
5cannabinol2.8917
6cannabigerol2.7114
7cannabidivarin2.5612
8cannabichromene2.4811
9lysophosphatidic acid2.4010
10tetrahydrocannabivarin2.208
11liquiritin2.208
12sb 7054982.087
13abt 1021.956
14voacangine1.956
15cbd1.102
16cannabidiol1.102
17Camphor0.691
18Framycetin0.691
19Leukotriene B40.691
20neomycin0.691

About TRPV1 as a Drug Target

TRPV1 (transient receptor potential cation channel subfamily V member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 20 compounds with documented TRPV1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TRPV1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.